Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome
Europace · 2023
DOI: 10.1093/europace/euad154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, 2023. Verfasst von Giovanna Nasilli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam…. Hauptthemen laut MEDLINE: Long QT Syndrome, Brugada Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Netherlands CardioVascular Research Initiative, Fondation Leducq, ZonMw Priority Medicines.
Abstract (Originalsprache)
Aims
SCN5A mutations are associated with various cardiac phenotypes, including long QT syndrome type 3 (LQT3), Brugada syndrome (BrS), and cardiac conduction disease (CCD). Certain mutations, such as SCN5A-1795insD, lead to an overlap syndrome, with patients exhibiting both features of BrS/CCD [decreased sodium current (INa)] and LQT3 (increased late INa). The sodium channel blocker mexiletine may acutely decrease LQT3-associated late INa and chronically increase peak INa associated with SCN5A loss-of-function mutations. However, most studies have so far employed heterologous expression systems and high mexiletine concentrations. We here investigated the effects of a therapeutic dose of mexiletine on the mixed phenotype associated with the SCN5A-1795insD mutation in HEK293A cells and human-induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs). Methods and results To assess only the chronic effects on trafficking, HEK293A cells transfected with wild-type (WT) SCN5A or SCN5A-1795insD were incubated for 48 h with 10 µm mexiletine followed by wash-out, which resulted in an increased peak INa for both SCN5A-WT and SCN5A-1795insD and an increased late INa for SCN5A-1795insD. Acute re-exposure of HEK293A cells to 10 µm mexiletine did not impact on peak INa but significantly decreased SCN5A-1795insD late INa. Chronic incubation of SCN5A-1795insD hiPSC-CMs with mexiletine followed by wash-out increased peak INa, action potential (AP) upstroke velocity, and AP duration. Acute re-exposure did not impact on peak INa or AP upstroke velocity, but significantly decreased AP duration.
Conclusion
These findings demonstrate for the first time the therapeutic benefit of mexiletine in a human cardiomyocyte model of SCN5A overlap syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam, Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
- Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias, Amsterdam, The Netherlands.
- Department of Anatomy and Embryology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
- Department NeuroFarBa, University of Florence, Viale Gaetano Pieraccini 6, 50139, Florence, Italy.
- The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
- Department of Medical Biology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
ORCID-Profile: Giovanna Nasilli, Loukia Yiangou, Chiara Palandri, Elisabetta Cerbai, Richard P Davis, Arie O Verkerk, Simona Casini, Carol Ann Remme
Förderung
- Netherlands CardioVascular Research Initiative
- Fondation Leducq
- ZonMw Priority Medicines
- ZonMw PSIDER
- DECIPHER
- Novo Nordisk Foundation
Zitieren
APA
Nasilli, G., Yiangou, L., Palandri, C., Cerbai, E., Davis, R. P., Verkerk, A. O., Casini, S., & Remme, C. A. (2023). Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome. Europace. https://doi.org/10.1093/europace/euad154
Vancouver
Nasilli G, Yiangou L, Palandri C, Cerbai E, Davis RP, Verkerk AO, et al. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome. Europace. 2023. doi:10.1093/europace/euad154
BibTeX
@article{Nasilli2023,
author = {Nasilli, Giovanna and Yiangou, Loukia and Palandri, Chiara and Cerbai, Elisabetta and Davis, Richard P and Verkerk, Arie O and Casini, Simona and Remme, Carol Ann},
title = {Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome},
journal = {Europace},
year = {2023},
doi = {10.1093/europace/euad154}
}
EUVIMED